308 related articles for article (PubMed ID: 29169614)
21. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
22. Clinical evaluation of human papillomavirus 16/18 oncoprotein test for cervical cancer screening and HPV positive women triage.
Yu L; Jiang M; Qu P; Wu Z; Sun P; Xi M; Qin Y; Liu X; Liao G; Lei X; Sun L; Zhang Y; Li Z; Chen W; Qiao YL
Int J Cancer; 2018 Aug; 143(4):813-822. PubMed ID: 29524206
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of alternately combining HPV viral load and 16/18 genotyping in secondary screening algorithms.
Luo H; Du H; Belinson JL; Wu R
PLoS One; 2019; 14(7):e0220200. PubMed ID: 31348794
[TBL] [Abstract][Full Text] [Related]
24. Defining Optimal Triage Strategies for hrHPV Screen-Positive Women-An Evaluation of HPV 16/18 Genotyping, Cytology, and p16/Ki-67 Cytoimmunochemistry.
Stanczuk GA; Baxter GJ; Currie H; Forson W; Lawrence JR; Cuschieri K; Wilson A; Patterson L; Govan L; Black J; Palmer T; Arbyn M
Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1629-1635. PubMed ID: 28887297
[No Abstract] [Full Text] [Related]
25. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
26. Risk stratification for cervical neoplasia using extended high-risk HPV genotyping in women with ASC-US cytology: A large retrospective study from China.
Tao X; Austin RM; Yu T; Zhong F; Zhou X; Cong Q; Sui L; Zhao C
Cancer Cytopathol; 2022 Apr; 130(4):248-258. PubMed ID: 34874615
[TBL] [Abstract][Full Text] [Related]
27. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women.
Hesselink AT; Heideman DA; Steenbergen RD; Coupé VM; Overmeer RM; Rijkaart D; Berkhof J; Meijer CJ; Snijders PJ
Clin Cancer Res; 2011 Apr; 17(8):2459-65. PubMed ID: 21389098
[TBL] [Abstract][Full Text] [Related]
28. Colposcopy referral rate can be reduced by high-risk human papillomavirus triage in the management of recurrent atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion cytology in Finland.
Jakobsson M; Tarkkanen J; Auvinen E; Häkkinen R; Laurila P; Tapper AM
Int J STD AIDS; 2012 Jul; 23(7):485-9. PubMed ID: 22844002
[TBL] [Abstract][Full Text] [Related]
29. Role of Human Papillomavirus DNA Load in Predicting the Long-term Risk of Cervical Cancer: A 15-Year Prospective Cohort Study in China.
Zhao X; Zhao S; Hu S; Zhao K; Zhang Q; Zhang X; Pan Q; Zhao F
J Infect Dis; 2019 Jan; 219(2):215-222. PubMed ID: 31067317
[TBL] [Abstract][Full Text] [Related]
30. Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study.
Agorastos T; Chatzistamatiou K; Moysiadis T; Kaufmann AM; Skenderi A; Lekka I; Koch I; Soutschek E; Boecher O; Kilintzis V; Angelidou S; Katsiki E; Hagemann I; Boschetti Gruetzmacher E; Tsertanidou A; Angelis L; Maglaveras N; Jansen-Duerr P
Int J Cancer; 2017 Aug; 141(3):519-530. PubMed ID: 28470689
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of partial genotyping with HPV16/18 for triage of HPV positive, cytology negative women in the COMPACT study.
Hanley SJB; Fujita H; Aoyama-Kikawa S; Kasamo M; Torigoe T; Matsuno Y; Noriaki S;
J Gynecol Oncol; 2021 Nov; 32(6):e86. PubMed ID: 34708593
[TBL] [Abstract][Full Text] [Related]
32. The effectiveness of human papillomavirus load, reflected by cycle threshold values, for the triage of HPV-positive self-samples in cervical cancer screening.
Song F; Du H; Wang C; Huang X; Qu X; Wei L; Belinson JL; Wu R;
J Med Screen; 2021 Sep; 28(3):318-324. PubMed ID: 32869705
[TBL] [Abstract][Full Text] [Related]
33. Clinical performance of Anyplex II HPV28 by human papillomavirus type and viral load in a referral population.
Baasland I; Romundstad PR; Eide ML; Jonassen CM
PLoS One; 2019; 14(1):e0210997. PubMed ID: 30673759
[TBL] [Abstract][Full Text] [Related]
34. Attributing oncogenic human papillomavirus genotypes to high-grade cervical neoplasia: which type causes the lesion?
van der Marel J; Berkhof J; Ordi J; Torné A; Del Pino M; van Baars R; Schiffman M; Wentzensen N; Jenkins D; Quint WG
Am J Surg Pathol; 2015 Apr; 39(4):496-504. PubMed ID: 25353286
[TBL] [Abstract][Full Text] [Related]
35. Extended Human Papillomavirus Genotyping to Predict Progression to High-Grade Cervical Precancer: A Prospective Cohort Study in the Southeastern United States.
Bukowski A; Hoyo C; Hudgens MG; Brewster WR; Valea F; Bentley RC; Vidal AC; Maguire RL; Schmitt JW; Murphy SK; North KE; Smith JS
Cancer Epidemiol Biomarkers Prev; 2022 Aug; 31(8):1564-1571. PubMed ID: 35654413
[TBL] [Abstract][Full Text] [Related]
36. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
Xu L; Oštrbenk A; Poljak M; Arbyn M
J Clin Virol; 2018 Jan; 98():37-42. PubMed ID: 29241150
[TBL] [Abstract][Full Text] [Related]
37. Risk stratification for cervical precancer and cancer by DH3-HPV partial genotyping and cytology in women attending cervical screening: A retrospective cohort study.
Fu Y; Li Y; Li X; Wang X; Lü W
J Med Virol; 2023 Feb; 95(2):e28482. PubMed ID: 36609841
[TBL] [Abstract][Full Text] [Related]
38. Prospective comparison of hybrid capture 2 and SPF₁₀-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China.
Dong L; Feng RM; Zhang L; Xu XQ; Zhao XL; Wang MZ; Qiao YL; Zhao FH
J Gynecol Oncol; 2017 Sep; 28(5):e66. PubMed ID: 28657227
[TBL] [Abstract][Full Text] [Related]
39. Clinical Performance of the BD Onclarity Extended Genotyping Assay for the Management of Women Positive for Human Papillomavirus in Cervical Cancer Screening.
Volesky KD; Magnan S; Mayrand MH; Isidean SD; El-Zein M; Comète E; Franco EL; Coutlée F
Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):851-857. PubMed ID: 35131879
[TBL] [Abstract][Full Text] [Related]
40. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience.
Veijalainen O; Kares S; Kujala P; Vuento R; Osuala V; Tirkkonen M; Luukkaala T; Kholová I; Mäenpää J
Cytopathology; 2019 Mar; 30(2):150-156. PubMed ID: 30421573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
